Skip to main content Skip to search Skip to main navigation
 Get a free Melatonin Spray with purchases over €100  Get a free Melatonin Spray with purchases over €100 X
Menu
Premium Nahrungsergänzungsmittel | artgerecht

Ixazomib: Mechanism, Dosage & Side Effects

Ixazomib is an oral cancer drug belonging to the class of proteasome inhibitors, used in the treatment of multiple myeloma.

Regular tips about health Regular tips about health
Lexicon Navigation

Things worth knowing about "Ixazomib"

Ixazomib is an oral cancer drug belonging to the class of proteasome inhibitors, used in the treatment of multiple myeloma.

What is Ixazomib?

Ixazomib is a second-generation proteasome inhibitor and the first orally administered agent of this drug class. It is marketed under the brand name Ninlaro and is approved for the treatment of multiple myeloma – a malignant disease of plasma cells in the bone marrow. Ixazomib is administered as ixazomib citrate, which is rapidly converted to its active form in the body.

Indication

Ixazomib is approved in combination with lenalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. This three-drug combination has demonstrated efficacy in clinical trials in slowing disease progression and extending progression-free survival.

Mechanism of Action

Ixazomib selectively inhibits the 26S proteasome complex, a central cellular organelle responsible for degrading misfolded or damaged proteins. By blocking the proteasome, ubiquitinated proteins accumulate within cancer cells, leading to:

  • Endoplasmic reticulum stress
  • Activation of apoptotic signaling pathways (programmed cell death)
  • Inhibition of tumor cell proliferation

Myeloma cells are particularly vulnerable to this type of stress because they produce large quantities of antibodies and therefore rely heavily on a functional proteasome.

Dosage and Administration

Ixazomib is administered orally as hard capsules. The recommended dose is 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle. The capsule should be taken at least one hour before or two hours after a meal. Dose adjustments may be necessary in patients with renal impairment or hepatic disease. Treatment is continued until disease progression or unacceptable toxicity occurs.

Side Effects

Like all cancer medicines, ixazomib can cause side effects. The most common include:

  • Hematological effects: Thrombocytopenia (low platelet count), neutropenia, anemia
  • Gastrointestinal complaints: Nausea, diarrhea, constipation, vomiting
  • Peripheral neuropathy: Tingling, numbness, or pain in the hands and feet
  • Skin reactions: Rash, dry skin
  • Infections: Increased susceptibility to infections
  • Edema: Swelling, particularly in the legs

Serious adverse events such as severe thrombocytopenia, hepatotoxicity, and thrombotic microangiopathy are less common but require close monitoring.

Treatment Context and Clinical Studies

The approval of ixazomib was largely based on the TOURMALINE-MM1 study, a phase III trial demonstrating that the triple combination of ixazomib, lenalidomide, and dexamethasone significantly prolonged median progression-free survival compared to placebo plus lenalidomide and dexamethasone. As the first all-oral proteasome inhibitor regimen, ixazomib offers patients a more convenient treatment option compared to intravenously or subcutaneously administered alternatives such as bortezomib or carfilzomib.

Interactions and Precautions

Ixazomib is metabolized primarily by CYP3A4. Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce the efficacy of ixazomib and should be avoided. Strong CYP3A4 inhibitors may increase drug exposure. Regular blood count monitoring is recommended during therapy. Ixazomib is contraindicated during pregnancy and breastfeeding.

References

  1. Moreau P et al. - Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016; 374(17):1621–1634.
  2. European Medicines Agency (EMA) - Ninlaro (Ixazomib): Summary of Product Characteristics. EMA, 2016. Available at: www.ema.europa.eu
  3. Rajkumar SV, Kumar S - Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2016; 91(1):101–119.

Most purchased products

Discount
natural iron supplement premium plantderived mineralcomplex?ts=1751927698

Average rating of 4.94 out of 5 stars

Natural Iron

For your iron balance

Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Gluten free
Lactose free
100% vegetarian fermentation
30 Capsules
30 Capsules
Sale price: €29.90 Regular price: €35.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
Discount
lactoferrin kapseln 60 premium eisenbindung immunschutz laktosefrei milch?ts=1751997240

Average rating of 4.85 out of 5 stars

Lactoferrin 60 Capsules

For your universal protection

As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Lactose free
Pure CLN
60 Capsules
60 Capsules
Sale price: €50.00 Regular price: €59.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
floral lactoferrin cln mundflora lutschtabletten?ts=1779887262

Average rating of 4.96 out of 5 stars

Floral

For Healthy Oral Flora & Dental Care

Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Sugar free
Lab tested
Non-GMO
Cologne List
Lactose free
Tooth friendly
GMP Quality
Clinical proofed
Pure CLN
30 lozenges
Regular price: €22.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.

The latest entries

3 Posts in this encyclopedia category

Lactic acid

Lactic acid (lactate) is an organic acid produced naturally in the body during energy metabolism. It plays a key role in muscle physiology, diagnostics, and food production.

Burosumab

Burosumab is a monoclonal antibody used to treat X-linked hypophosphatemia. It inhibits FGF23 and helps restore normal phosphate levels in the blood.

Lorlatinib

Lorlatinib is a targeted cancer drug used to treat ALK- or ROS1-positive non-small cell lung cancer. It inhibits mutated kinases and effectively crosses the blood-brain barrier.

Related search terms: Ixazomib